Search

Friction stir processing (FSP) manufacturing technology was used to fabricate medium Mn advanced high-strength steel in this study. The mechanical properties and microstructure of the steel fabricated using FSP were investigated. The steel obtained a total elongation of 35.1% and a tensile strength of 1034.6 MPa, which is about 59% higher than that of the steel without FSP. After FSP, a gradient structure occurs along the thickness direction. Specifically, across the thickness direction from the base material zone to the transition zone and finally to the stirring zone, both the grain size and austenite fraction decrease while the dislocation density increases, which results from the simultaneous effect of severe plastic deformation and recrystallization during FSP. Due to the gradient structure, an obvious difference in the strain across the thickness direction of the steel occurs during the deformation process, resulting in significant hetero-deformation-induced (HDI) strengthening. The deformation mechanism analysis reveals that HDI strengthening and dislocation strengthening are the main factors in the improvement in the strength–ductility balance. The obtained knowledge sheds light on the process of fabricating medium Mn steels with excellent properties using FSP manufacturing technology. [ABSTRACT FROM AUTHOR]

This research aimed to develop a supercritical fluid (SCF) technique for preparing a particulate form of itraconazole (ITZ) with good dissolution and bioavailability characteristics. The ITZ particulate solid dispersion was formulated with hydroxypropyl methylcellulose, Pluronic F-127, and L-ascorbic acid. Aggregated particles showed porous structure when examined by scanning electron microscopy. Powder X-ray diffraction and Fourier transform infrared spectra indicated an interaction between ITZ and excipients and showed that ITZ existed in an amorphous state in the composite solid dispersion particles. The solid dispersion obtained by the SCF process improved the dissolution of ITZ in media of pH 1.0, pH 4.5, and pH 6.8, compared with a commercial product (Sporanox(®)), which could be ascribed to the porous aggregated particle shape and amorphous solid state of ITZ. While the solid dispersion did not show a statistical improvement (P=0.50) in terms of oral bioavailability of ITZ compared with Sporanox(®), the C max (the maximum plasma concentration of ITZ in a pharmacokinetic curve) of ITZ was raised significantly (P=0.03) after oral administration. Thus, the SCF process has been shown to be an efficient, single step process to form ITZ-containing solid dispersion particles with good dissolution and oral bioavailability characteristics.